application number: anda 040620 › drugsatfda_docs › ... · the test and reference formulations...
TRANSCRIPT
![Page 1: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/1.jpg)
CENTER FOR DRUG EVALUATION AND RESEARCH
APPLICATION NUMBER:
ANDA 040620
BIOEQUIVALENCE REVIEWS
![Page 2: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/2.jpg)
![Page 3: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/3.jpg)
![Page 4: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/4.jpg)
![Page 5: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/5.jpg)
![Page 6: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/6.jpg)
![Page 7: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/7.jpg)
![Page 8: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/8.jpg)
![Page 9: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/9.jpg)
![Page 10: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/10.jpg)
![Page 11: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/11.jpg)
![Page 12: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/12.jpg)
![Page 13: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/13.jpg)
![Page 14: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/14.jpg)
![Page 15: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/15.jpg)
![Page 16: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/16.jpg)
![Page 17: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/17.jpg)
![Page 18: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/18.jpg)
![Page 19: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/19.jpg)
![Page 20: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/20.jpg)
![Page 21: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/21.jpg)
![Page 22: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/22.jpg)
![Page 23: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/23.jpg)
![Page 24: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/24.jpg)
![Page 25: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/25.jpg)
![Page 26: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/26.jpg)
![Page 27: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/27.jpg)
![Page 28: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/28.jpg)
![Page 29: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/29.jpg)
![Page 30: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/30.jpg)
![Page 31: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/31.jpg)
![Page 32: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/32.jpg)
![Page 33: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/33.jpg)
![Page 34: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/34.jpg)
![Page 35: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/35.jpg)
![Page 36: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/36.jpg)
![Page 37: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/37.jpg)
![Page 38: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/38.jpg)
![Page 39: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/39.jpg)
![Page 40: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/40.jpg)
![Page 41: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/41.jpg)
![Page 42: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/42.jpg)
![Page 43: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/43.jpg)
![Page 44: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/44.jpg)
![Page 45: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/45.jpg)
![Page 46: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/46.jpg)
![Page 47: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/47.jpg)
![Page 48: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/48.jpg)
![Page 49: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/49.jpg)
![Page 50: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/50.jpg)
![Page 51: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/51.jpg)
![Page 52: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/52.jpg)
![Page 53: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/53.jpg)
![Page 54: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/54.jpg)
![Page 55: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/55.jpg)
![Page 56: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/56.jpg)
![Page 57: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/57.jpg)
![Page 58: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/58.jpg)
![Page 59: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/59.jpg)
![Page 60: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/60.jpg)
![Page 61: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/61.jpg)
![Page 62: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/62.jpg)
![Page 63: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/63.jpg)
![Page 64: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/64.jpg)
![Page 65: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/65.jpg)
![Page 66: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/66.jpg)
![Page 67: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/67.jpg)
![Page 68: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/68.jpg)
![Page 69: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/69.jpg)
![Page 70: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/70.jpg)
![Page 71: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/71.jpg)
![Page 72: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/72.jpg)
![Page 73: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/73.jpg)
![Page 74: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/74.jpg)
![Page 75: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/75.jpg)
![Page 76: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/76.jpg)
![Page 77: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/77.jpg)
![Page 78: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/78.jpg)
![Page 79: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/79.jpg)
![Page 80: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/80.jpg)
![Page 81: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/81.jpg)
![Page 82: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/82.jpg)
![Page 83: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/83.jpg)
![Page 84: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/84.jpg)
![Page 85: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/85.jpg)
![Page 86: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/86.jpg)
![Page 87: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/87.jpg)
![Page 88: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/88.jpg)
![Page 89: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/89.jpg)
![Page 90: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/90.jpg)
![Page 91: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/91.jpg)
![Page 92: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/92.jpg)
![Page 93: APPLICATION NUMBER: ANDA 040620 › drugsatfda_docs › ... · The test and reference formulations are identical, for both 40 mg/mL and 80 mg/mL, as shown in the Appendix, page 24](https://reader034.vdocuments.us/reader034/viewer/2022042315/5f03e4d37e708231d40b4a54/html5/thumbnails/93.jpg)
TRANSCRIPT
CENTER FOR DRUG EVALUATION AND RESEARCH
APPLICATION NUMBER:
ANDA 040620
BIOEQUIVALENCE REVIEWS